Natalizumab for multiple sclerosis: A case in point for the impact of translational neuroimmunology

Afsaneh Shirani, Olaf Stüve

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Advances in translational neuroimmunology over the last two decades have revolutionized the treatment of relapsing forms of multiple sclerosis. A pathological hallmark of multiple sclerosis is the presence of leukocytes in the areas of disease activity in the CNS.Natalizumab inhibits the trafficking of lymphocytes from the blood into the brain and spinal cord by blocking the adhesion molecule a4-integrin. Representing the enormous success of a molecular targeted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multiple sclerosis. However, only a few months after its approval, natalizumab was withdrawn from the market because of an unanticipated life threatening adverse effect: progressive multifocal leukoencephalopathy. Natalizumab was later reintroduced with required adherence to a strict monitoring program. In this article, we review the bench-to-bedside journey of natalizumab, along with the lessons learned from postmarketing studies.

Original languageEnglish (US)
Pages (from-to)1381-1386
Number of pages6
JournalJournal of Immunology
Volume198
Issue number4
DOIs
Publication statusPublished - Feb 15 2017

    Fingerprint

Cite this

Natalizumab for multiple sclerosis : A case in point for the impact of translational neuroimmunology. / Shirani, Afsaneh; Stüve, Olaf.

In: Journal of Immunology, Vol. 198, No. 4, 15.02.2017, p. 1381-1386.

Research output: Contribution to journalArticle